---
source_pdf: "https://drive.google.com/file/d/1v7GJoIDO35XQxVQ-ieJR9ecfZ-hKXhll/view?usp=drivesdk"
drive_folder: "Portfolio/Prudentia"
type: portfolio
company: Prudentia
ingested: 2025-12-24
original_filename: "Prudentia Sciences Series A (1).pdf"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/1v7GJoIDO35XQxVQ-ieJR9ecfZ-hKXhll/view?usp=drivesdk)

## Slide 1: Company Overview

**Prudentia Sciences**
Accelerated Insights, Prudent Decisions

**Confidential- Do not distribute**

Company Overview
Prudentia Sciences
2025

September 2025
Confidential - Do Not Distribute
Prudentia Sciences

## Slide 2: Prudentia Sciences is building the future of drug dealmaking

**Prudentia Sciences**

**Confidential**

Prudentia Sciences is building the
future of drug dealmaking with:

*   AI powered clinical evaluation of drugs
*   Valuation tied to clinical progress and risks

**Confidential - Do not distribute**

September 2025
Confidential - Do Not Distribute
2

## Slide 3: Team Introductions

**Prudentia Sciences**

**Team Introductionfidential-**

**Prudentia Sciences Team**

*   **Sadiqa Mahmood**
    CEO & Founder
    Ex - Health Catalyst, Broad Institute of Harvard & MIT, Mass General Brigham

*   **Nate Fox**
    Chief Technology Officer
    Ex - H1, Ribbon Health, Microsoft

*   **Sharon Tan**
    Scientific Lead
    Ex - Ultragenyx, enGene, Enzyvent, Genzyme, Boston Scientific

*   **Ben Klein**
    Head of Partnerships
    Ex - Flatiron Health, Optum

*   **John Reynders, PhD**
    Head of Strategy
    Ex - Moderna, Alexion, J&J

**not distribute**

September 2025
Confidential - Do Not Distribute
3

## Slide 4: Scientific Advisory Board and Expert Panel

**Prudentia Sciences**

**Scientific Advisory Board and Expert Panel**

**Comidential Do**

*   **Mark Currie, PhD (SAB Chair)**
    Board Director, Ironwood Pharmaceuticals
    Board Director, Science Exchange
    Pioneered discovery of drugs like Celebrex, Lunesta, and Linzess

*   **David Nicholson, PhD**
    Executive Vice President and Chief R&D Officer at Allergan
    Chief Technology Officer and EVP, R&D at Bayer
    Pioneered discovery of anti-PD1 cancer drug Keytruda® (pembrolizumab)

*   **Ana Cristina Puga, MD, PhD**
    Head of Early Development, Sarepta Therapeutics
    VP, Clinical Development CNS, Bluerock Therapeutics
    Medical Director, Rare Diseases, Sanofi

*   **Mary Lynne Hedley**
    Board Member, Eli Lilly and Veeva
    Venture Partner, Third Rock Ventures
    Pioneered discovery and approval of Tesaro

*   **Matt Leoni, MD**
    CMO, Merida Biosciences
    SVP Global Clinical Development, Cerevel Therapeutics
    Senior Director, CNS, Global Clinical Development, Otsuka
    Lead Medical Director, Neuroscience, US Early Development, Novartis

*   **Stuart Chaffee**
    CEO, QuantX Biosciences
    Co-Founder and Head of BD, Kymera Therapeutics (IPO)
    CBO of Affinivax (acquired by GSK)
    CBO & CFO, Praxis Precision Medicines (IPO)

**Company Logos:**
Lilly, Cerevel, Novartis, Otsuka, Praxis, Kymera, Merck, Veeva, AbbVie

**ate**

October 2025
Confidential - Do Not Distribute
4

## Slide 5: The Challenge in Drug Transactions across Life Sciences Sector Unlocking Value in $1.5T Drug Dealmaking Market

**Prudentia Sciences**

The Challenge in Drug Transactions across Life Sciences Sector
Unlocking Value in ST Drug Dealmaking Market

“What is the highest value decision
can make for my pipeline?”

These questions reflect the realities of the current market landscape. At the outset, there are several challenges including:

*   **? Immense Capital at Risk**
*   **Systemic Inefficiencies**

**Cifidential- Do not distribute**

"How can I beat the competition for
the next great asset?"

*   **? Data Overload, Insight Scarcity**
*   **? Gap Valuation and Clinical Risks**
*   **? Lack of Enterprise Tools**

“How do I optimize valuation of
my asset?"

September 2025
Confidential - Do Not Distribute
5

## Slide 6: Ideal State AI Native Approach for Data Driven Deal Making

**Prudentia Sciences**

Ideal State
Al Native Approach for Data Driven Deal Making

P

*   **Rocket Icon:** Accelerate speed to decision from data room access to submission of a competitive bid.
*   **Expand/Contract Arrows Icon:** Scale diligence team and deal throughput per year.
*   **Magnifying Glass Icon:** Ensure no stone left unturned, and quickly identify value driver or risk.
*   **Graph/Bars Icon:** Achieve optimal bid based on clinical milestones and risks.

**Confidential- Do not distribute**

September 2025
Confidential - Do Not Distribute
6

## Slide 7: Prudentia is building scientific due diligence platform for global drug asset transactions In just 2 years, we have

**Prudentia Sciences**

Prudentia is building scientific due diligence platform for global drug asset transactions
In just 2 years, we have

**wonfidenti**

*   **>70**
    Drug Assessments
    6 Therapeutic Areas

*   **~$5m**
    End of 2025 Sales
    Pharma ACV >$1m
    Biotech & VC ACV >$125k

*   **>8**
    End of 2025
    Enterprise Customers

**$17.21m**
Pipeline deal amount

**Do not distribute**

**Deals in active discussions: 37**

| Category     | Count |
| :----------- | :---- |
| Biopharma    | 14    |
| Biotech      | 7     |
| Investor/VC  | 13    |
| LS consulting | (not explicitly numbered for LS consulting, implied remaining from 37) |

Highly active pipeline with significant pharma, biotech & investor interest

7

## Slide 8: Prudentia is Unleashing a $264m Annual Revenue Opportunity Capturing 5% of a $5.3B TAM

**Prudentia Sciences**

Prudentia is Unleashing a $264m Annual Revenue Opportunity
Capturing 5% of a $5.3B5

**Confider**

**$10.5B TAM**

**Prudentia Platform**
Drug diligence and staging

**Total Addressable Market (TAM) Breakdown:**

| Segment               | TAM          | Description                                                                 |
| :-------------------- | :----------- | :-------------------------------------------------------------------------- |
| Global Pharma         | $8.25b       | 5500 Global Pharma, Average deal size (ARR) = ~$1.5m                        |
| Biotech               | $1.87b       | 15,000 Biotech, Average deal size (ARR) = ~$125k                            |
| Financial Institutions | $437m        | 455 Financial Institutions*, Average deal size (ARR) = ~$95k (VCs) - $2m (IB) |

**not distribute**

August 2025
Confidential - Do Not Distribute
*103 VCs + 149 PEs + 203 Investment Banks

## Slide 9: Our Solution End-to-End Drug Assessment & Valuation Platform

**Prudentia Sciences**

Our Solution
End-to-End Drugent & Valuation Platform

**Corifidential- Do not**

**Prudentia Sciences**
**Platform Features**

*   Traceable AI
*   SOC 2 Enabled

**Platform Modules:**

*   **Prism**
    Drug Assessment
*   **Pinnacle**
    Value Simulation
*   **Pulse**
    Staging of Drugs
*   **Prospect**
    Top-of-funnel synthesis

**Ω Expert in the loop**

**tribute**

August 2025
Confidential - Do Not Distribute

## Slide 10: Prudentia Solutions Mapped to Drug Due Diligence Process End-to-End Deal Management, Diligence & Valuation Platform

**Prudentia Sciences**

Prudentia Solutions Mapped to Drug Due Diligence Process
End-to-End Deal Management, Diligence & Valuation Platform

**Stages**

**Activity**

**Tident**

**Prudentia Solutions**

*   **Stage I**
    *   **Opportunity Screening and Prioritization**
        *   Dynamic Deal Funnel Management & Opportunity Sizing
        *   On-Strategy Alignment w/ Portfolio Priority
    *   **Solution:** Prospect

*   **Stage II**
    *   **Asset Assessment and Valuation**
        *   Domain-Specific Diligence w/ Expert Alignment
        *   Deep Market Review & Optimal Valuation Scenarios
        *   Competitive Landscape Assessment
    *   **Solution:** Prism, Pinnacle & Pattern

*   **Stage III**
    *   **Deal Execution and Integration**
        *   Decision Analysis and Governance
        *   Deal Execution and Post-Diligence Integration

**Deal Flow Diagram:**

*   **>1000 Deals** (e.g. sources from JPM, BIO, etc.)
    *   (Flows into) **Prudentia Sciences**
        *   (Flows into) **<20 high quality deals**
            *   (Flows into) **Deal Executed**

**al- Do not distribute**

September 2025
Confidential - Do Not Distribute
10

## Slide 11: Success Metrics How Our Partners Measure Success

**Prudentia Sciences**

Success Metrics
How Our Partneriential- Do not distoute

**Metrics and Outcomes:**

| Metric             | Current State       | Prudentia State | Description                                          |
| :----------------- | :------------------ | :-------------- | :--------------------------------------------------- |
| **Diligence Cycle** | 12 Weeks            | **1 Day**       | Accelerated Diligence Cycle                          |
| **Screening**      | 2 Weeks             | **Instant**     | Quick Screening of High Value Opportunities          |
| **Scientific Review** | 5 Weeks             | **1 Hour**      | Reduce Diligence Burden and Risk for Transaction Teams |
| **Scenario Simulation** | 4 Weeks             | **Instant**     | Rapid Simulation of 100s of Scenarios with Clinical Progress and Risks |

August 2025
Confidential - Do Not Distribute
11

## Slide 12: The Prudentia Advantage

**Prudentia Sciences**

The Prudentia Advantage

*   **Accelerate Deal Timelines with Quick Decision Making**
    *   Rapidly disqualify bad deals
    *   Focus on high-potential, transformative opportunities
    *   Reduce diligence costs and deploy resources to high-value opportunities

*   **Dual-Sided Platform Driving Network Effects**
    *   Uniquely serves both buy-side and sell-side transactions across biotechs, pharma, and investors
    *   Creates a powerful network effect and comprehensive market coverage

*   **From Static Snapshots to Continuous, Contextual Diligence**
    *   Move beyond static due diligence to an "always on" platform capturing evolving asset value – a critical, unmet need.
    *   Contextualize clinical, market, regulatory data sets with the asset information.

**o not distribute**

Confidential - Do not distribute

## Slide 13: Case Study Biotech diligence identified previously unknown risks and drive meaningful NPV impact

**Prudentia Sciences**

**C**

Case Study
Biotech diligence identified previously unknown risks and drive meaningful NPV impact

**They eviously**

**Biotech Drug Assessment with Valuation and Risk Simulation**

**SITUATION**

*   A biotechnology company approached Prudentia Sciences with the need to thoroughly assess their early-stage development asset in the Neurology.
*   The company was pursuing external investment and needed support in staging their asset, identifying potential risks, and driving valuation estimates.

**APPROACH**

*   Company leveraged Prudentia's Prism and Pinnacle solutions to comprehensively assess their asset across multiple indications and understand NPV scenarios based on numerous variables pulled from the diligence.
*   Company integrated their data room directly with Prudentia's solution.

**IMPACT**

*   Prudentia solution identified 2 high-risk safety concerns which were previously unknown by Company. This allowed them to proactively address with supplemental data prior to approaching potential investors, directly impacting their NPV.

**enti**

**Do not distribute**

**“Prudentia's platform helped us rapidly identify potential NPV-impacting variables within our safety & toxicology profile, and with such speed that we were able to proactively supplement prior to investor presentations.”**
**– CEO, Biotech**

Confidential - Do not distribute

## Slide 14: Case Study Venture Capital firm identified key value drivers and risks

**Prudentia Sciences**

Case Study
Venture Capital firm identified key value drivers and risks

**Biotech Diligence & Valuation / Risk Simulation**

**SITUATION**

*   A venture capital firm had an influx of potential investment opportunities and needed to rapidly perform an in-depth diligence on one key potential biotech investment - time was a limiting factor.

**APPROACH**

*   Company leveraged Prudentia's Prism to assess biotech asset, including clinical, scientific and commercial components.
*   Company integrated their data room directly with Prudentia's solution (>80 data files)

**IMPACT**

*   Prudentia delivered a comprehensive diligence assessment in <15 minutes upon completion of the data room upload.
*   Prism identified a number of potential risks across key domains such as regulatory and CMC, however ultimately showcased a valuable diligence that enabled the VC firm to move forward with the investment quickly.

**ential- Do not distribute**

**"I wish I had this tool 4-5 months ago, as I was working on a diligence process with several colleagues where we evaluated over 100+ immunology & oncology assets...This would be invaluable for the many other newco/venture teams that are also going through this similar process.”**
**— Partner, VC**

Confidential - Do not distribute

## Slide 15: Case Study Biopharma addressing major enterprise-wide pain points via AI-powered diligence

**Prudentia Sciences**

Case Study
Biopharma addressing major enterprise-wide pain points via Al-powered diligence

**Biotech Diligence & Valuation / Risk Simulation**

**SITUATION**

*   A top 20 global biopharma company engaged with Prudentia to help address key pain points in their pursuit for external innovation - specifically:
    *   Slow diligence process that lacks enterprise technology
    *   Painful stakeholder management process to support diligence completion
    *   Lack of consistent framework for assessing external assets

**APPROACH**

*   Company engaged with Prudentia to address these pain points via Prudentia's enterprise platform (Prospect, Prism, Pinnacle)
*   Prudentia presented holistic enterprise approach:
    *   **Prospect** - help manage influx of top-of-funnel deals to identify potential opportunities for further evaluation
    *   **Prism** - dramatically accelerate scientific, regulatory and commercial diligence from weeks to hours
    *   **Pinnacle** - evaluate potential valuation and risk scenarios based on commercial, regulatory, and scientific findings

**Ongoing**

**Do not distribute**

**“We are constantly chasing internal experts for diligence and continue to run an inefficient process. Prudentia is doing this in minutes and we have full provenance of data.”**
**— VP, BD&L - Top 200 Biopharma**

Confidential - Do not distribute

## Slide 16: Competitive Landscape

**Prudentia Sciences**

Competitive Landscap

**Prudentia Sciences**

**Confidential- Do**

**Y-axis: AI-native Platform (top) to Consulting Services (bottom)**
**X-axis: Market Intelligence (left) to Comprehensive Scientific Assessment + Valuation (right)**

**Company Positioning:**

*   **AI-native Platform:**
    *   Prudentia Sciences (Top right quadrant, furthest right on X-axis)
    *   Evaluate (mid-left on AI-native level)
    *   Clarivate™ (mid-left on AI-native level, below Evaluate)
    *   AlphaSense (mid-left on AI-native level, below Clarivate)

*   **Tech-enabled Consulting Services:** (Empty in the middle of the graph)

*   **Consulting Services:**
    *   QLS (Bottom-middle, on Financial Modeling)
    *   BCG (Bottom-right, on Scientific Assessment)
    *   LEK™ (Bottom-right, on Scientific Assessment)

**not distribute**

**Axes Labels:**

*   **Y-axis (from top to bottom):**
    *   AI-native Platform
    *   Tech-enabled Consulting Services
    *   Consulting Services

*   **X-axis (from left to right):**
    *   Market Intelligence
    *   Financial Modeling
    *   Scientific Assessment
    *   Comprehensive Scientific Assessment + Valuation

Confidential - Do not distribute
16

## Slide 17: Raising $25m Use of Proceeds

**Prudentia Sciences**

Raising $25m
**Use of Proceedsonfidential - Do not distribute**

**Pie Chart Data - Use of Proceeds ($25m Total):**

| Category              | Percentage |
| :-------------------- | :--------- |
| Scale Core Platform   | 35.0%      |
| Build Language Models | 30.0%      |
| New Solutions         | 20.0%      |
| Expand to China       | 15.0%      |

August 2025
Confidential - Do Not Distribute
17

## Slide 18: Vision

**Prudentia Sciences**

Vision

**Confidential- Do not distribute**

**End to end platform for drug dealmaking**

**Platform Stages:**

*   **Staging**
    Prepare for evaluation

*   **Diligence**
    Clinical assessment

*   **Valuation**
    Optimal bid

*   **Deal Execution**
    Partnering

August 2025
Confidential - Do Not Distribute
18